Johnson & Johnson (JNJ) shares slipped 5.7% after it reported Q3 adjusted EPS down 7.5% to $2.59, beating expectations of $2.53. Revenue increased 5.9% to $25.40bn, slightly above the $25.38bn consensus. Weak international medical device sales, pressure from China’s pricing policies and Middle East disruptions weighed on MedTech, while the company raised its full year 2026 guidance.